Physician profile
Jack H Klie
NPI 1992876080
$1,781.65
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $627 · 2021: $445 · 2022: $86.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $772.80 | 2019-2022 | |
| Amgen INC. | $186.91 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.45 | 2019-2022 | |
| Boston Scientific Corporation | $179.15 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $144.79 | 2019-2021 | |
| Amarin Pharma, INC. | $53.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.21 | 2021-2022 | |
| Daiichi Sankyo INC. | $45.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.94 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $40.33 | 2019-2020 | |
| Pfizer INC. | $36.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.29 | 2019 | |
| Novo Nordisk INC | $20.76 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Klie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.